These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 16419308)

  • 1. FDA approves Aptivus (tipranavir).
    Pham PA
    Hopkins HIV Rep; 2005 Jul; 17(4):6-7. PubMed ID: 16419308
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA approves tipranavir.
    IAPAC Mon; 2005 Jul; 11(7):190. PubMed ID: 16676422
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA approval: tipranavir.
    Sax PE
    AIDS Clin Care; 2005 Aug; 17(8):78. PubMed ID: 16193574
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA notifications. Accelerated approval of tipranavir.
    AIDS Alert; 2005 Nov; 20(11):131. PubMed ID: 16363051
    [No Abstract]   [Full Text] [Related]  

  • 5. Aptivus in the hotseat. Excerpts from the FDA hearings.
    Huff B
    GMHC Treat Issues; 2005; 19(5-6):6-8. PubMed ID: 16193577
    [No Abstract]   [Full Text] [Related]  

  • 6. Aptivus capsules granted full FDA approval.
    AIDS Patient Care STDS; 2007 Nov; 21(11):889-90. PubMed ID: 18338430
    [No Abstract]   [Full Text] [Related]  

  • 7. Tipranavir (Aptivus): approval cautiously recommended.
    James JS
    AIDS Treat News; 2005 May; (412):2-3. PubMed ID: 16047408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA notifications. Tentative approval to Aptivus for combination ART.
    AIDS Alert; 2007 Dec; 22(12):144. PubMed ID: 18411486
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-HIV agents. Tipranavir in treatment-experienced PHAs.
    TreatmentUpdate; 2005; 17(1):4-5. PubMed ID: 17225315
    [No Abstract]   [Full Text] [Related]  

  • 10. Tipranavir.
    Gallant J
    Drugs; 2003; 63(15):1619-20. PubMed ID: 12887269
    [No Abstract]   [Full Text] [Related]  

  • 11. Tipranavir: PNU 140690, tipranivir.
    Drugs R D; 2006; 7(1):55-62. PubMed ID: 16620137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA notifications. FDA approves new atazanavir labeling.
    AIDS Alert; 2011 Mar; 26(3):33-4. PubMed ID: 21539041
    [No Abstract]   [Full Text] [Related]  

  • 13. Tipranavir: new drug. HIV protease inhibitor. A last resort.
    Prescrire Int; 2006 Dec; 15(86):217-9. PubMed ID: 17167925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New black box warning for ritonavir-boosted tipranavir.
    Ryan CT
    AIDS Clin Care; 2006 Aug; 18(8):72. PubMed ID: 16906669
    [No Abstract]   [Full Text] [Related]  

  • 15. Anti-HIV agents. Unexpected results from a tipranavir study.
    TreatmentUpdate; 2004; 16(3):6-7. PubMed ID: 17216836
    [No Abstract]   [Full Text] [Related]  

  • 16. New protease inhibitor offers clinicians hope for better salvage therapy.
    Murphy MJ
    HIV Clin; 2006; 18(1):1-3. PubMed ID: 16838417
    [No Abstract]   [Full Text] [Related]  

  • 17. Reyataz dosing options discussed. Excerpts from the FDA atazanavir hearing.
    Huff B
    GMHC Treat Issues; 2003 Jun; 17(6):8-11. PubMed ID: 12913962
    [No Abstract]   [Full Text] [Related]  

  • 18. FDA notifications. New tipranavir solution approved.
    AIDS Alert; 2008 Aug; 23(8):92. PubMed ID: 18724491
    [No Abstract]   [Full Text] [Related]  

  • 19. [Tipranavir (used with ritonavir)].
    Taéron C
    Rev Infirm; 2006 Jan; (117):39-40. PubMed ID: 16502825
    [No Abstract]   [Full Text] [Related]  

  • 20. [Perspectives: hope for therapy experienced patients. Tipranavir shows superior effectiveness with comparable safety].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():44-5. PubMed ID: 16385873
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.